Loading stock…

Amgen Inc. (AMGN) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

AMGNAmgen

Revenue FY25$36.8B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+63%10

EPS growth, FY27E+6%5

EPS growth, FY28E+4%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 4%/yr).

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 12%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

WEAKNESSES

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+13%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+44%9

3-year return+69%6

5-year return+131%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +69% over three years and +131% over five, ahead of 60% of the market.

It's up 44% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+13%) and so far this year (+29%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Amgen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AMGNAmgen

Revenue FY25$36.8B

GROWTH RATING↗

WEAK34 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+63%10

EPS growth, FY27E+6%5

EPS growth, FY28E+4%5

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 4%/yr).

WATCH

A mid-pack grower, ahead of 34% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 12%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

WEAKNESSES

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+13%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+44%9

3-year return+69%6

5-year return+131%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +69% over three years and +131% over five, ahead of 60% of the market.

It's up 44% over the past year, now 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+13%) and so far this year (+29%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Amgen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Amgen Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Amgen. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Amgen. Get the full investment case.

Premium